B S Gostout
Affiliation: Mayo Clinic
- TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer riskBobbie S Gostout
Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Gynecol Oncol 88:326-32. 2003..We evaluated immune response genes in the HLA region of chromosome 6 to see if individual or interactive associations with cervical cancer risk could be identified...
- Guidelines for referral of the patient with an adnexal massBobbie S Gostout
Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Obstet Gynecol 49:448-58. 2006..Premenopausal women should be referred if the CA 125 is elevated above 200 U/mL, there is an evidence of metastatic disease or ascites, or strong family history of breast or ovarian cancer...
- Two cases of coincident carcinomas of the head and neck and the uterine cervixBobbie S Gostout
Department of Obstetrics and Gynecology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Gynecol Oncol 85:376-80. 2002..Human papillomavirus (HPV) is an independent risk factor for select head and neck carcinomas and most uterine cervix carcinomas. We report two patients with synchronous diagnoses of cervical cancer and HPV-related head and neck cancer...
- Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposureA Rust
Department of Dermatology, Biochemistry and Molecular Biology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Am Acad Dermatol 44:681-6. 2001..In addition, HPV type 62 was found in a brush specimen of the uterine cervix. This case report suggests an association between psoriasis, HPV infection, and UVR exposure, in onset of SCC...
- Prevention, diagnosis, and treatment of cervical cancerHarry J Long
Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:1566-74. 2007..Current recommendations for surgical treatment, concurrent chemotherapy, and radiation therapy and recent advances in systemic therapy for advanced or metastatic cervical cancer are reviewed...
- Secondary cytoreduction in the management of recurrent uterine leiomyosarcomaRobert L Giuntoli
The Kelly Gynecologic Oncology Service, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, Maryland 21287, USA
Gynecol Oncol 106:82-8. 2007..To identify effective treatment options for patients with recurrent uterine leiomyosarcoma (LMS)...
- Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behaviorRobert L Giuntoli
Kelly Gynecologic Oncology Service, Johns Hopkins University, Baltimore, Maryland, USA
J Reprod Med 52:1001-10. 2007..To determine the prognostic accuracy of current diagnostic criteria for uterine smooth muscle tumors...
- Malignant melanoma in the 21st century: the emerging molecular landscapeAleksandar Sekulic
Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
Mayo Clin Proc 83:825-46. 2008..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
- Aggressive surgical effort and improved survival in advanced-stage ovarian cancerGiovanni D Aletti
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota 55905, USA
Obstet Gynecol 107:77-85. 2006..However, the extent of surgical resection required to achieve optimal cytoreduction is controversial. Our goal was to estimate the effect of aggressive surgical resection on ovarian cancer patient survival...
- Screening for cervical cancer and initial treatment of patients with abnormal results from papanicolaou testingJohn B Bundrick
Division of General Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 80:1063-8. 2005..Testing for HPV as an adjunct to cervical cytology for primary screening is now considered reasonable for many women older than 30 years...
- Validation of referral guidelines for women with pelvic massesSamuel S Im
University of California Irvine Medical Center, Orange, California 92668, USA
Obstet Gynecol 105:35-41. 2005..They are based on patient age, CA 125 level, physical findings, imaging study results, and family history. Although the guidelines are evidence-based, their predictive value in distinguishing cancers from benign masses is unknown...
- Consensus-degenerate hybrid oligonucleotide primers (CODEHOP) for the detection of novel papillomaviruses and their application to esophageal and tonsillar carcinomasJonathan E Baines
Tumor Biology Program, Mayo Clinic, Rochester, MN, USA
J Virol Methods 123:81-7. 2005..These primers should facilitate the search for novel papillomaviruses...
- Prophylactic oophorectomy in premenopausal women and long-term healthLynne T Shuster
Department of Internal Medicine, Women s Health Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Menopause Int 14:111-6. 2008..To review the data on long-term outcomes in women who underwent prophylactic bilateral oophorectomy, a common surgical procedure that has more than doubled in frequency since the 1960s...
- Diaphragm resection for ovarian cancer: technique and short-term complicationsWilliam Cliby
Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, United States
Gynecol Oncol 94:655-60. 2004..Oncol. 82 (2001) 489). The aim of this study was to assess postoperative complications of DR in OC...
- Identification of cervical cancer markers by cDNA and tissue microarraysYan Chen
Department of Molecular and Cell Biology, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
Cancer Res 63:1927-35. 2003..It is hoped that with additional development, some of these markers will improve the interpretation of cervical screening tests and provide useful information for patient management decisions...
- Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associationsScott E Strome
Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota 55905, USA
Clin Cancer Res 8:1093-100. 2002..The role of human papilloma virus (HPV) in the pathogenesis and biological behavior of tonsillar squamous cell carcinoma (TSCC) are areas of intense investigation...
- Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical stagingAndrea Mariani
Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Gynecol Oncol 109:11-8. 2008..To prospectively assess pelvic and para-aortic lymph node metastases in endometrial cancer with lymphatic dissemination, emphasizing the examination of para-aortic metastases relative to the inferior mesenteric artery (IMA)...
- Host genetic polymorphism analysis in cervical cancerEric S Calhoun
Mayo Foundation for Medical Education and Research, Rochester, MN 55905, USA
Clin Chem 48:1218-24. 2002..Identifying host determinants of viral persistence may help to better understand the mechanisms of tolerance and may lead to the development of tests that can allow more focused follow-up of high-risk individuals...
- Pelvic Castleman disease presenting as vaginal occlusionGlenn A Gaunt
Section of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
Obstet Gynecol 100:1082-5. 2002..Castleman disease is a lymphoreticular disorder, which may be clinically silent. However, systemic manifestations can occur, which include generalized adenopathy and life-threatening bronchiolitis obliterans...
- Common fragile sites are preferential targets for HPV16 integrations in cervical tumorsErik C Thorland
Department of Biochemistry and Molecular Biology Mayo Clinic, Rochester, MN 55905, USA
Oncogene 22:1225-37. 2003..2), and FRA17B (17q23). Finally, our data suggest that cellular genes, such as Notch 1, are disrupted by the HPV16 integrations, which may contribute to the malignant phenotype...
- Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologistsYvonne Collins
University of Illinois, Chicago, IL, USA
Gynecol Oncol 102:552-62. 2006..This article is intended to provide gynecologic oncologists with a comprehensive background in modern cervical cancer prevention strategies...
- Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapyRobert L Giuntoli
Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Gynecol Oncol 89:460-9. 2003..We evaluated the predictive value of several proposed prognostic indicators and the effect of surgical management and adjuvant therapy on clinical outcome associated with leiomyosarcoma (LMS) of the uterus...
- Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeonGiovanni D Aletti
Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Gynecol Oncol 100:33-7. 2006..We investigated the impact of clinical and surgical-pathologic factors at the time of initial exploration on the ability to achieve optimal cytoreduction...
- Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinomaMatthew J Ferber
Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905, USA
Oncogene 22:7233-42. 2003..Our results suggest that the sites of HPV18 integration are nonrandom and may play an important role in the development of cervical tumors...
- Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell linesSean C Dowdy
Department of Obstetrics and Gynecology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Gynecol Oncol 99:126-34. 2005..To measure mRNA expression levels of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines and to determine if DNA methylation is involved in the control of PEG3 expression...
- Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervixStephen A Contag
Section of Gynecologic Surgery, Mayo Clinic, 200 SW First Street, Rochester, MN 55905, USA
Gynecol Oncol 95:610-7. 2004..We sought to identify differences between normal squamous epithelium (NSQ) and glandular epithelium (NGL) of the uterine cervix and their malignant variants: squamous cell cancer (SCC) and adenocarcinoma (ACA)...